亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

275 All-in-one CAR T cell platform for safe and effective targeting of metastatic castration-resistant prostate cancer

作者
Nour Shobaki,Yutong Deng,Menelik Duey,Julia Nguyen,Tomomi Sanomachi,Jidapa Janpathompong,Martina Spiga,Ting-Jia Fan,Decheng Song,Fang Liu,Mei Qing Ji,Khatuna Gabunia,Mansi Deshmukh,Huijun Wei,Ethan Sun,Andrew J. Rech,Wei Liu,Neil C. Sheppard,Vivek Narayan,John Scholler
出处
期刊: 卷期号:: A305-A305
标识
DOI:10.1136/jitc-2025-sitc2025.0275
摘要

Background Metastatic castration-resistant prostate cancer (mCRPC) is a lethal, treatment-refractory stage of disease, frequently associated with bone metastases and poor prognosis. While chimeric antigen receptor (CAR) T cell therapy holds promise for mCRPC, clinical translation has been limited by toxicities associated with validated targets such as PSMA. In our first-in-human trials of PSMA-CAR T cells armored with a dominant-negative TGF-β receptor II (dnTGFβRII) ( NCT03089203, NCT04227275), and in the ongoing REGN5678 αPSMA×CD28 bispecific study (NCT03972657), good responses were observed but accompanied by grade ≥3 cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), and immune effector cell-associated neurotoxicity syndrome (ICANS). In addition to toxicity, antigen heterogeneity—specifically, the growth of PSMA-negative tumor clones— decreases the therapeutic efficacy of CAR T cells.Methods To address these challenges, we developed a multi-pronged, all-in-one CAR T cell platform with triple-armoring and dual-targeting functionality. Our design includes: (1) targeting the prostate cancer-associated antigen STEAP2 to reduce on-target/off-tumor toxicity; (2) localized secretion of αPSMA×CD28 bispecific to activate bystander T cells against PSMA-positive variants while limiting systemic toxicity; (3) fine-tuning CD28 affinity to enhance anti-tumor activity and reduce CRS risk; and (4) overcoming immunosuppression by armoring CAR T cells with dnTGFβRII. Bispecific secretion is restricted to NFAT-activated CAR T cells upon STEAP2-engagement, confining CD28 co-stimulation to the tumor microenvironment (TME) and broaden safety profile.We tested our all-in-one CAR T cell platform in vitro using a panel of TGF-β-secreting human prostate cancer cell lines with varying STEAP2 and PSMA expression to discriminate STEAP2-CAR- versus αPSMA×CD28-mediated cytotoxicity. For in vivo efficacy, we established subcutaneous (s.c.), intravenous (i.v.), and intraosseous (i.o.) xenograft models in immunodeficient mice to mimic primary tumors, systemic disease, and bone metastases, respectively. To evaluate safety, we successfully validated a novel huPSMA knock-in (KI) mouse model that recapitulates human PSMA tissue expression.Results We successfully engineered multiple αPSMA×CD28 constructs within a dnTGFβRII-armored STEAP2-CAR T cell backbone. Bispecific secretion was confirmed by ELISA and dual-binding assays to PSMA+ tumor cells and CD28+ T cells. Engineered CAR T cells demonstrated robust in vitro cytotoxicity against heterogeneous prostate cancer cell lines. Furthermore, our preliminary in vivo results show high potency in tumor killing using the LNCaP (STEAP2+, PSMA+) tumor model.Conclusions This all-in-one platform integrates tumor specificity, dual targeting, localized immune activation, and TME resistance, offering a promising strategy for improving the safety and efficacy of CAR T cell therapy in mCRPC and other solid tumors.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
humorlife完成签到,获得积分10
2秒前
现代的冰海完成签到,获得积分10
3秒前
3秒前
zyyicu完成签到,获得积分10
4秒前
希望天下0贩的0的应助被369ninja采纳,获得10
5秒前
霸气惜文完成签到,获得积分10
9秒前
大模型的应助被369ninja采纳,获得10
23秒前
26秒前
369ninja发布了新的文献求助10
30秒前
懦弱的代云完成签到,获得积分10
40秒前
如意涵雁完成签到,获得积分10
45秒前
华仔的应助被爱学习的doge采纳,获得10
47秒前
英姑的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
韩_发布了新的文献求助10
1分钟前
彭于晏的应助被科研通管家采纳,获得10
1分钟前
充电宝的应助被sun采纳,获得10
1分钟前
1分钟前
甜甜的文轩完成签到,获得积分10
1分钟前
爱笑的芝麻完成签到,获得积分10
1分钟前
阿双完成签到,获得积分10
1分钟前
sun发布了新的文献求助10
1分钟前
1分钟前
2分钟前
灵巧的绮琴完成签到,获得积分10
2分钟前
整齐的天问完成签到,获得积分10
2分钟前
Qian完成签到 ,获得积分10
2分钟前
细腻绮完成签到,获得积分10
2分钟前
2分钟前
天天快乐的应助被情深以挽采纳,获得10
2分钟前
369ninja发布了新的文献求助10
3分钟前
玛琳卡迪马完成签到,获得积分10
3分钟前
molihuakai的应助被科研通管家采纳,获得10
3分钟前
3分钟前
英俊的谷蓝完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808444
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557352
邀请新用户注册赠送积分活动 2478958